Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Medigene to Present at Upcoming Conferences | ||
By: GlobeNewswire - 19 Feb 2024 | Back to overview list |
|
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024 Presentation Date: February 28, 2024, 5:30 pm local time Pre-conference workshop Date: February, 27, 2024, 1 pm local time Panel discussion Date: February 28, 2024, 12:30 pm local time Corporate presentation – East-West Biopharma Summit 2024 Date: March 5, 2024 Members of Medigene’s management team will be available for one-on-one meetings at the events. Please contact Dr. Fotini Vogiatzi at f.vogiatzi@medigene.com to schedule a meeting at either one of the conferences. --- end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens (CTAs) and neoantigens, armor and enhance these TCR-T cells to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its in-house therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit https://medigene.com/. Medigene Pamela Keck In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list. |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |